Esperion Therapeutics Inc (ESPR)
2.37
+0.25
(+11.79%)
USD |
NASDAQ |
May 07, 12:36
Esperion Therapeutics Research and Development Expense (Quarterly): 17.74M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.74M |
| September 30, 2023 | 14.88M |
| June 30, 2023 | 22.10M |
| March 31, 2023 | 31.38M |
| December 31, 2022 | 33.03M |
| September 30, 2022 | 29.14M |
| June 30, 2022 | 32.43M |
| March 31, 2022 | 24.32M |
| December 31, 2021 | 27.62M |
| September 30, 2021 | 25.33M |
| June 30, 2021 | 25.07M |
| March 31, 2021 | 27.95M |
| December 31, 2020 | 41.96M |
| September 30, 2020 | 35.28M |
| June 30, 2020 | 34.99M |
| March 31, 2020 | 34.70M |
| December 31, 2019 | 38.23M |
| September 30, 2019 | 48.28M |
| June 30, 2019 | 42.79M |
| March 31, 2019 | 46.31M |
| December 31, 2018 | 49.47M |
| September 30, 2018 | 41.55M |
| June 30, 2018 | 39.52M |
| March 31, 2018 | 40.94M |
| Date | Value |
|---|---|
| December 31, 2017 | 33.44M |
| September 30, 2017 | 40.06M |
| June 30, 2017 | 38.25M |
| March 31, 2017 | 35.86M |
| December 31, 2016 | 24.88M |
| September 30, 2016 | 13.50M |
| June 30, 2016 | 9.698M |
| March 31, 2016 | 9.791M |
| December 31, 2015 | 7.956M |
| September 30, 2015 | 7.247M |
| June 30, 2015 | 7.209M |
| March 31, 2015 | 7.39M |
| December 31, 2014 | 6.20M |
| September 30, 2014 | 7.174M |
| June 30, 2014 | 6.528M |
| March 31, 2014 | 5.40M |
| December 31, 2013 | 7.338M |
| September 30, 2013 | 3.483M |
| June 30, 2013 | 3.10M |
| March 31, 2013 | 2.093M |
| December 31, 2012 | 1.654M |
| September 30, 2012 | 2.456M |
| June 30, 2012 | 2.330M |
| March 31, 2012 | 1.557M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
14.88M
Minimum
Sep 2023
48.28M
Maximum
Sep 2019
30.91M
Average
31.38M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| United Therapeutics Corp | 104.10M |
| Dynavax Technologies Corp | 14.12M |
| Heron Therapeutics Inc | 10.95M |
| Aldeyra Therapeutics Inc | 6.184M |
| Deciphera Pharmaceuticals Inc | 58.60M |